DE60222422D1 - Mutationen in ionenkanälen - Google Patents

Mutationen in ionenkanälen

Info

Publication number
DE60222422D1
DE60222422D1 DE60222422T DE60222422T DE60222422D1 DE 60222422 D1 DE60222422 D1 DE 60222422D1 DE 60222422 T DE60222422 T DE 60222422T DE 60222422 T DE60222422 T DE 60222422T DE 60222422 D1 DE60222422 D1 DE 60222422D1
Authority
DE
Germany
Prior art keywords
subject
mutations
ion channels
ion channel
undergone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60222422T
Other languages
English (en)
Inventor
John Charles Mulley
Louise Anne Harkin
Leanne Michelle Dibbens
Hilary Anne Phillips
Sarah Elizabeth Heron
Samuel Frank Berkovic
Ingrid Eileen Scheffer
Robyn Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR6452A external-priority patent/AUPR645201A0/en
Priority claimed from AUPS0910A external-priority patent/AUPS091002A0/en
Priority claimed from AUPS2292A external-priority patent/AUPS229202A0/en
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Application granted granted Critical
Publication of DE60222422D1 publication Critical patent/DE60222422D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
DE60222422T 2001-07-18 2002-07-08 Mutationen in ionenkanälen Expired - Lifetime DE60222422D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR6452A AUPR645201A0 (en) 2001-07-18 2001-07-18 Mutations in ion channels
AUPS0910A AUPS091002A0 (en) 2002-03-05 2002-03-05 Mutations in ion channels
AUPS2292A AUPS229202A0 (en) 2002-05-13 2002-05-13 Novel mutations
PCT/AU2002/000910 WO2003008574A1 (en) 2001-07-18 2002-07-08 Mutations in ion channels

Publications (1)

Publication Number Publication Date
DE60222422D1 true DE60222422D1 (de) 2007-10-25

Family

ID=27158306

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60222422T Expired - Lifetime DE60222422D1 (de) 2001-07-18 2002-07-08 Mutationen in ionenkanälen

Country Status (9)

Country Link
US (2) US20050074764A1 (de)
EP (2) EP1407013B1 (de)
JP (1) JP2005501536A (de)
AT (1) ATE373089T1 (de)
AU (1) AU2002318972B8 (de)
CA (1) CA2454073C (de)
DE (1) DE60222422D1 (de)
NZ (2) NZ542048A (de)
WO (1) WO2003008574A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002318972B8 (en) 2001-07-18 2007-08-09 Bionomics Limited Mutations in ion channels
US7709225B2 (en) * 2001-07-18 2010-05-04 Bionomics Limited Nucleic acids encoding mutations in sodium channels related to epilepsy
AU2003904154A0 (en) * 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
ATE385795T1 (de) 2002-07-30 2008-03-15 Wyeth Corp Parenterale formulierungen mit einem rapamycin hydroxyester
AU2003901425A0 (en) 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
AU2004263548B2 (en) * 2003-08-07 2007-09-13 Bionomics Limited Mutations in ion channels
CA2541836A1 (en) * 2003-10-13 2005-04-21 Bionomics Limited A diagnostic method for neonatal or infantile epilepsy syndromes
AU2005318278A1 (en) * 2004-12-24 2006-06-29 Ares Trading S.A. Compositions and methods for treating mental disorders
WO2006133508A1 (en) * 2005-06-16 2006-12-21 Bionomics Limited Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene
US20100311610A1 (en) * 2008-02-01 2010-12-09 Chromocell Corporation CELL LINES AND METHODS FOR MAKING AND USING THEM (As Amended)
EP2770325A1 (de) 2013-02-26 2014-08-27 Institut du Cerveau et de la Moelle Epiniere-ICM Mutationen von DEPDC5 zur Diagnose von epileptischen Funktionsstörungen, Erkrankungen oder Leiden
JP7312451B2 (ja) 2018-01-26 2023-07-21 国立大学法人東海国立大学機構 受容体タンパク質を標的とする治療薬、検査薬、受容体タンパク質に結合する抗体、及び分子標的薬のスクリーニング方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4971903A (en) * 1988-03-25 1990-11-20 Edward Hyman Pyrophosphate-based method and apparatus for sequencing nucleic acids
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
NO175199C (no) 1991-12-05 1994-09-14 Kvaerner Fjellstrand As Flerskrogfartöy
AU701228B2 (en) * 1995-06-28 1999-01-21 University Of Bonn Diagnostic and treatment methods relating to Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)
US5646040A (en) 1995-06-30 1997-07-08 Millennium Pharmaceutical, Inc. Mammalian tub gene
AU2002318972B8 (en) * 2001-07-18 2007-08-09 Bionomics Limited Mutations in ion channels
US6331614B1 (en) * 1998-12-23 2001-12-18 Myriad Genetics, Inc. Human CDC14A gene
WO2001038564A2 (en) * 1999-11-26 2001-05-31 Mcgill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
US6703439B2 (en) * 2000-02-09 2004-03-09 Mitsui Chemicals, Inc. Polyolefin resin composition and polyolefin film prepared from the same
AUPQ749100A0 (en) 2000-05-12 2000-06-08 Bionomics Limited New epilespy gene
NZ522888A (en) 2000-06-20 2005-01-28 Bionomics Ltd Mutations in the gamma aminobutyric acid type A receptor subunit ( GABA A ) associated with epilepsy
AUPQ882600A0 (en) 2000-07-18 2000-08-10 Bionomics Limited Mutations in ion channels
US6661614B2 (en) * 2000-09-27 2003-12-09 Seagate Technology Llc Magnetless actuator for disc drive
AUPR220300A0 (en) 2000-12-20 2001-01-25 Bionomics Limited New epilepsy gene
AUPR492201A0 (en) 2001-05-10 2001-06-07 Bionomics Limited Novel mutation
AU2003904154A0 (en) 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
US7709225B2 (en) * 2001-07-18 2010-05-04 Bionomics Limited Nucleic acids encoding mutations in sodium channels related to epilepsy
US7282336B2 (en) * 2001-07-18 2007-10-16 Bionomics Limited Method of diagnosing epilepsy
WO2003046147A2 (en) * 2001-11-26 2003-06-05 Bristol-Myers Squibb Company Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
AU2003901425A0 (en) 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
WO2006133508A1 (en) * 2005-06-16 2006-12-21 Bionomics Limited Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene

Also Published As

Publication number Publication date
EP1407013B1 (de) 2007-09-12
NZ542048A (en) 2008-04-30
US20050074764A1 (en) 2005-04-07
EP1852505A1 (de) 2007-11-07
NZ530258A (en) 2006-01-27
AU2002318972B2 (en) 2007-03-08
CA2454073A1 (en) 2003-01-30
US7989182B2 (en) 2011-08-02
WO2003008574A1 (en) 2003-01-30
JP2005501536A (ja) 2005-01-20
EP1407013A1 (de) 2004-04-14
EP1852505B1 (de) 2010-03-31
CA2454073C (en) 2012-08-28
ATE373089T1 (de) 2007-09-15
US20100136623A1 (en) 2010-06-03
AU2002318972A1 (en) 2003-03-03
EP1407013A4 (de) 2005-06-22
AU2002318972B8 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
DE60222422D1 (de) Mutationen in ionenkanälen
IL182761A0 (en) Identification of jak2 mutation in polycythemia vera
HK1131744A1 (en) Toll like receptor 3 antagonists, methods and uses toll
DK1706424T3 (da) FC-region varianter
TWI365610B (en) Systems and methods for scalably encoding and decoding data
HK1086283A1 (en) Antibodies that bind cell-associated ca 125/0722p and methods of use thereof
ATE446314T1 (de) Methode zur reinigung von fsh
SI2185686T1 (sl) Dendritične celice
AR015687A2 (es) Gen aislado que codifica acil transferasa
WO2005027710A3 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
WO2005094569A8 (en) Ion channel
WO2003040315A3 (en) Method of encoding characteristics of a biological sample
ATE412751T1 (de) Menschliche tak1 und für diese kodierende dna
WO2006046994A3 (en) Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk
EE200100234A (et) PRV-1-geen ja selle kasutamine
ATE318933T1 (de) Nukleinsäurefragmente zur identifizierung von dechlorierenden bakterien
ATE447586T1 (de) Fprl1-liganden und deren verwendung
DE69930370D1 (de) Testisspezifische, menschliche proteinase, svph1-8
NO20020064D0 (no) Chlamysin B antibakterielt protein, gen som koder for dette samt et ekspresjonssystem for dette
NO20090666L (no) Nye ketolaser for fremstilling av ketokarotenoider i Tagetes
DE602005018326D1 (de) Für orotat-transporter codierende markergene
DE69939583D1 (de) Chondrosarcom-assoziierte gene
ATE517181T1 (de) Rekombinante carboxypeptidase b
UY27053A1 (es) Polimorfismos de nucleótidos simples humanos
WO2005031341A3 (en) Methods for predicting development of insulin resistance

Legal Events

Date Code Title Description
8332 No legal effect for de